Pieris Pharmaceuticals R&D Day

New York, November 19, 2019

Pieris Pharmaceuticals’ [PIRS] R&D Day at Convene (530 5th Ave) featuring Sally E Wenzel, Geoffrey Ku, and Michael Curran. Registration and lunch will be served at 12PM and presentations will take place from 12:30-3:30PM. To RSVP, please email ncolangelo@troutgroup.com.

Tuesday, November 19, 2019          |        Convene Event Space

12:30 – 3:30 PM           |          530 5th Avenue




Michael A. Curran, PhD
MD Anderson’s Associate Professor of Immunology & co-Scientific Director of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) program that coordinates development and production of clinical immunotherapeutic antibodies. Trained in Dr. Jim Allison’s lab at MSK and earned SITC’s Presidential Award for immunologic studies of 4-1BB agonist antibodies.

Geoffrey Y. Ku, MD
Assistant Attending Physician and Head, Esophagogastric Section, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering; PI on multiple studies of HER2+ tumors with clinical expertise of GI malignancies, esophageal and gastric cancers, as well as new chemotherapies.

Anuradha Ray, PhD
Image result for Anuradha Ray, PhD
Professor of Medicine, Department of Immunology and UPMC Endowed Chair in Lung Immunology Medicine, University of Pittsburgh

Sally E. Wenzel, MD
Professor of Medicine, Chair of the Department of Environmental and Occupational Health, the Director of the University of Pittsburgh Asthma Institute, and a member of the Cellular and Molecular Pathology Graduate Training Program. Global expert in severe asthma and pioneered the concept of asthma phenotypes, including the progression of molecular phenotyping.

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Pieris Pharmaceuticals, Inc. [PIRS] $199 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]